LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Cell Therapy (ISCT) in London, UK, May 3-6, 2017. This year marks the 25th anniversary of the ISCT, a global society that unites clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into clinical practice. HemaCare will meet with its customers and European distributors at the conference and showcase its growing portfolio for cell therapy developers around the world.
“Attending this meeting enables us to capture the latest developments in cell therapy and better serve our customer needs,” said Pete van der Wal, Chief Executive Officer for HemaCare. “The field of cell therapy is rapidly evolving. Our products and services are embedded in some of the most critical phases of translational research, enabling scientists to work with high quality human cells from our well-characterized donor pool.”
The conference is being held at ExCel London Conference Center. Look for us there, or view our products and services at www.hemacare.com.
About HemaCare
HemaCare specializes in the customization of human-derived biological products and services for customer’s research and cell therapy protocols. HemaCare’s network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCare’s isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare's extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.
For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit www.hemacare.com.